|Day Low/High||42.41 / 42.76|
|52 Wk Low/High||38.95 / 45.62|
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
The charges were related to an interest-rate problem.
As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.
Consumer spending should be more than solid given wage increases.
Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?
So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.
Some French companies will get a temporary windfall, but others will need to pay more tax.
Tesla and General Motors are among this week's names showing reversal patterns.
Investors keep an eye on another busy slate of earnings.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.
Sarepta CEO Ed Kaye said he's stepping down.
Sanofi SA agreed to a U.S. Department of Justice a $19.8 million fine for overcharging the U.S. Department of Veteran Affairs.
Why the name is sagging, and what it will take to spur the sector higher.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
Hollywood's lack of originality shines through with 15 remakes and sequels this year.
There are nearly too many surging sectors to count.
SNY has become much stronger since late October; buy here and above $44.